We are thrilled to announce that as of December 2024, our flagship product has been successfully deployed at the Imaging Department of the Chinese University of Hong Kong (Shenzhen) Affiliated Hospital and is currently undergoing clinical evaluation. This marks a significant milestone in advancing the clinical application of our AI-powered solution for personalized liver cancer treatment.
About the Deployment
- Empowering Healthcare with Innovative Technology:
Our system integrates imaging, pathology, and genomic data to deliver comprehensive disease assessments and precise treatment recommendations for liver cancer patients. Leveraging advanced deep learning models, it automates liver imaging analysis and combines genomic insights to assist doctors in recommending targeted therapies, predicting outcomes, and evaluating prognoses. - Intelligent Decision Support:
The system also offers a similar patient search function, enabling physicians to reference comparable cases and refine personalized treatment plans further. - On the Path to Clinical Validation:
Currently, the product is being thoroughly evaluated in a real clinical setting at the Imaging Department of CUHK (Shenzhen) Affiliated Hospital, where its performance and feasibility are being rigorously assessed.
Looking Ahead
This deployment represents a critical step in translating cutting-edge technology into clinical practice, paving the way for broader adoption across more healthcare institutions. As the system undergoes continuous optimization and evaluation, we are confident it will bring significant value to the field of liver cancer precision treatment.
We firmly believe in the transformative power of technology in healthcare. This collaboration is not only a strong testament to the technical strength of our product but also an essential milestone on the journey toward clinical adoption. Moving forward, we remain committed to delivering innovative, efficient, and precise solutions for liver cancer patients and the medical community at large.